CAJ | 학술논문

肝移植目前被认为是治疗门静脉高压症的最有效措施，脾切除是治疗肝硬化合并上消化道出血患者的有效方法。早期报导认为，脾切除可减少抗体的产生，降低排斥反应发生率，并且治疗肝移植术后持续性血小板减少症。近年来，不断有报导提出脾切除可增加肝移植患者术后的感染率、病死率及动静脉血栓形成的危险性。脾切除对肝移植患者的影响，目前尚未见详细报道。
간이식목전피인위시치료문정맥고압증적최유효조시，비절제시치료간경화합병상소화도출혈환자적유효방법。조기보도인위，비절제가감소항체적산생，강저배척반응발생솔，병차치료간이식술후지속성혈소판감소증。근년래，불단유보도제출비절제가증가간이식환자술후적감염솔、병사솔급동정맥혈전형성적위험성。비절제대간이식환자적영향，목전상미견상세보도。
Liver transplantation is considered to be the most effective measures for the treatment of portal hypertension(PHT) at present. Splenectomy is a effective treatment for patients with hepatocirrhosis with upper gastrointestinal bleeding. Early reports that splenectomy can decrease the production of antibodies, reduce rejection rate, and treat persistent thrombocytopenia after liver transplantation. In recent years, there have been reports suggested splenectomy can increase the liver transplantation in patients with postoperative infection rate, mortality and the risk of venous thrombosis. The effect of splenectomy in patients with liver transplantation, has yet to see the detailed report.